The global breast cancer therapeutics market is set
to increase in value from $10.4 billion in 2014 to $17.2 billion by 2021, at a
Compound Annual Growth Rate (CAGR) of 7.3%, according to new research.
The company’s latest report states that this strong
growth will be primarily due to substantial increases in the prevalence of
breast cancer, with rates of the disease expected to rise over the forecast
period due to an aging population, changing lifestyles and higher survival
rates.
According to Senior Analyst, says that the
introduction of several new therapies will help to drive breast cancer
treatment market growth by 2021.
Senior Analyst explains: “In terms of upcoming breast
cancer treatments, the overall pipeline is strong, with 743 products, and the
early pipeline has many experimental molecules designed to target novel
pathways.
“Promising pipeline drugs include abemaciclib,
buparlisib, LEE 011, Olaparib and NeuVax, all of which are expected to be
approved within the forecast period and have demonstrated significant clinical
benefits in trials. In addition, rapid uptake of premium-priced biologics, such
as Perjeta and Kadcyla, in all settings of the disease will contribute to the
market growth.”
Despite this, the analyst notes that the late-stage
breast cancer pipeline is weak, with only 6% of candidates in Phase III of
development, and targeted therapies, currently unrepresented by marketed
products, almost non-existent within this phase.
The report also states that the market will face some
limitations due to patent expirations creating substantial opportunity for
generic and biosimilar manufacturers.
Senior Analyst continues: “The patents for a number
of key breast cancer drugs, including Afinitor, Avastin and Herceptin, are
expected to expire during the forecast period. However, the use of combinations
of branded therapies in both the early-stage and metastatic settings will
increase the Annual Cost of Therapy (ACoT) and offset the impact of patent
expiries.
“For example, the ACoT for the combination of Perjeta
with Herceptin is three times that of Herceptin monotherapy in both adjuvant
and metastatic settings in the US. Therefore, even though Herceptin is set to
expire in the near future, this will be offset by the approval of newer
combination therapies and the growth of current premium therapies.”
Breast Cancer Therapeutics in Major Developed Markets
to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising
Incidence report provides analysis of the breast cancer treatment pipeline,
stratified by stage of development, molecule type and mechanism of action. It
includes information on the current clinical and commercial landscape, unmet
needs, and annualized market data from 2014 and forecast to 2021.
This report was built using data and information
sourced from proprietary databases, primary and secondary research, and
in-house analysis conducted by Publisher’s team of industry experts.
For more information Visit at: http://mrr.cm/oVV
Find all Therapeutic
Report at: http://www.marketresearchreports.com/therapeutic
No comments:
Post a Comment
Note: only a member of this blog may post a comment.